中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 10
Oct.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(10): 2412-2415

Application and progress of the contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) in "M" lesions

DOI: 10.3969/j.issn.1001-5256.2022.10.041

  • Department of Ultrasound, Shengjing Hospital, China Medical University, Shenyang 110004, China

Research funding:

Liaoning Province Science and Technology Foundation Project (2021JH2/10300114)

More Information
  • Corresponding author: TANG Shaoshan, tangss@sj-hospital.org(ORCID: 0000-0002-6020-991X)
  • Received Date: 2022-03-08
  • Accepted Date: 2022-04-11
  • Published Date: 2022-10-20
    Abstract
  • Clinically, there are still substantial differences between hepatocellular carcinoma (HCC) and non-HCC liver malignancies in terms of risk factors, pathogenesis, biological behaviors, treatment selections, prognosis, and prevention measurement. The liver imaging reporting and data system (LI-RADS) M (LR-M) classification criteria in the contrast-enhanced ultrasound LI-RADS (CEUS LI-RADS) can help differentiate HCC from non-HCC malignancies. This review discussed and summarized recent advancements in differential diagnosis of HCC from non-HCC using the LR-M criteria and speculated future directions in the field, i.e., how CEUS LI-RADS distinguish HCC from intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma cholangiocarcinoma, and liver metastasized and benign tumors. It also discussed differences between CEUS LI-RADS and CT/MRI LI-RADS in diagnosis of liver neoplasms and SonazoidⓇ modified CEUS LI-RADS in differential diagnosis of HCC from non-HCC.

     

    • FullText(HTML)
  • loading
    • References(36)
  • [1]
    LIU ZC, LI ZX, ZHANG Y, et al. Interpretation on the report of Global Cancer Statistics 2020[J/CD]. J Multidiscip Cancer Manag(Electr Vers), 2021, 7(2): 1-13. DOI: 10.12151/JMCM.2021.02-01.

    刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J/CD]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13. DOI: 10.12151/JMCM.2021.02-01.
    [2]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [3]
    SAPISOCHIN G, FIDELMAN N, ROBERTS JP, et al. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma[J]. Liver Transpl, 2011, 17(8): 934-942. DOI: 10.1002/lt.22307.
    [4]
    MASSARWEH NN, EL-SERAG HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017, 24(3): 1073274817729245. DOI: 10.1177/1073274817729245.
    [5]
    WILSON SR, BURNS PN, KONO Y. Contrast-enhanced ultrasound of focal liver masses: a success story[J]. Ultrasound Med Biol, 2020, 46(5): 1059-1070. DOI: 10.1016/j.ultrasmedbio.2019.12.021.
    [6]
    BARTOLOTTA TV, TERRANOVA MC, GAGLIARDO C, et al. CEUS LI-RADS: a pictorial review[J]. Insights Imaging, 2020, 11(1): 9. DOI: 10.1186/s13244-019-0819-2.
    [7]
    FOWLER KJ, POTRETZKE TA, HOPE TA, et al. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma[J]. Abdom Radiol (NY), 2018, 43(1): 149-157. DOI: 10.1007/s00261-017-1196-2.
    [8]
    HU YX, SHEN JX, HAN J, et al. Diagnosis of non-hepatocellular carcinoma malignancies in patients with risks for hepatocellular carcinoma: CEUS LI-RADS versus CT/MRI LI-RADS[J]. Front Oncol, 2021, 11: 641195. DOI: 10.3389/fonc.2021.641195.
    [9]
    ZHANG JL, GE H, WU WJ. Diagnostic value of contrast-enhanced LI-RADS classification criteria in hepatocellular carcinoma[J]. Chin J Gen Pract, 2021, 19(5): 833-837. DOI: 10.16766/j.cnki.issn.1674-4152.001929.

    张家玲, 葛晖, 武文娟. 超声造影LI-RADS分类标准对肝细胞癌的诊断价值[J]. 中华全科医学, 2021, 19(5): 833-837. DOI: 10.16766/j.cnki.issn.1674-4152.001929.
    [10]
    HAN H, KONG WT, QIU YD, et al. Diagnostic value of liver imaging reporting and data system for hepatocellular carcinoma by contrast-enhanced ultrasound[J]. J Clin Ultrasound Med, 2017, 19(8): 505-509. DOI: 10.16245/j.cnki.issn1008-6978.2017.08.001.

    韩浩, 孔文韬, 仇毓东, 等. LI-RADS超声造影分类标准对肝细胞癌的诊断价值[J]. 临床超声医学杂志, 2017, 19(8): 505-509. DOI: 10.16245/j.cnki.issn1008-6978.2017.08.001.
    [11]
    ZHENG W, LI Q, ZOU XB, et al. Evaluation of contrast-enhanced US LI-RADS version 2017: application on 2020 liver nodules in patients with hepatitis B infection[J]. Radiology, 2020, 294(2): 299-307. DOI: 10.1148/radiol.2019190878.
    [12]
    DING JM, QIN ZY, WANG F. Development and clinical application of contrast enhanced ultrasound liver imaging reporting and data system[J]. J Clin Hepatol, 2022, 38(2): 466-470. DOI: 10.3969/j.issn.1001-5256.2022.02.043.

    丁建民, 秦正义, 王芳. 超声造影肝脏影像报告和数据管理系统发展现状及临床应用进展[J]. 临床肝胆病杂志, 2022, 38(2): 466-470. DOI: 10.3969/j.issn.1001-5256.2022.02.043.
    [13]
    LI F, LI Q, LIU Y, et al. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017[J]. Eur Radiol, 2020, 30(1): 461-470. DOI: 10.1007/s00330-019-06317-2.
    [14]
    CHEN LD, RUAN SM, LIANG JY, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound[J]. World J Gastroenterol, 2018, 24(33): 3786-3798. DOI: 10.3748/wjg.v24.i33.3786.
    [15]
    CHEN LD, RUAN SM, LIN Y, et al. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS[J]. Eur Radiol, 2019, 29(8): 4249-4257. DOI: 10.1007/s00330-018-5927-8.
    [16]
    SHIN J, LEE S, BAE H, et al. Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: A meta-analysis[J]. Liver Int, 2020, 40(10): 2345-2352. DOI: 10.1111/liv.14617.
    [17]
    LI J, YANG L, MA L, et al. Diagnostic accuracy of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) for differentiating between hepatocellular carcinoma and other hepatic malignancies in high-risk patients: a meta-analysis[J]. Ultraschall Med, 2021, 42(2): 187-193. DOI: 10.1055/a-1309-1568.
    [18]
    ZHAO ZL, TANG SS, PENG SS, et al. The diagnostic value of the LI-RADS classification of contrast-enhanced ultrasound in small hepatocellular carcinoma[J]. J China Med Univ, 2021, 50(7): 641-645. DOI: 10.12007/j.issn.0258-4646.2021.07.014.

    赵子路, 唐少珊, 彭珊珊, 等. 超声造影LI-RADS分类在小肝癌诊断中的应用价值[J]. 中国医科大学学报, 2021, 50(7): 641-645. DOI: 10.12007/j.issn.0258-4646.2021.07.014.
    [19]
    LIU GJ, WANG W, LU MD, et al. Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Liver Cancer, 2015, 4(4): 241-252. DOI: 10.1159/000367738.
    [20]
    HUANG JY, LI JW, LING WW, et al. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?[J]. World J Gastroenterol, 2020, 26(27): 3938-3951. DOI: 10.3748/wjg.v26.i27.3938.
    [21]
    YANG J, ZHANG YH, LI JW, et al. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. World J Gastroenterol, 2020, 26(46): 7325-7337. DOI: 10.3748/wjg.v26.i46.7325.
    [22]
    LI R, YANG D, TANG CL, et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography[J]. BMC Cancer, 2016, 16: 158. DOI: 10.1186/s12885-016-2156-x.
    [23]
    HUANG XW, HUANG Y, CHEN LD, et al. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma[J]. J Med Ultrason (2001), 2018, 45(2): 231-241. DOI: 10.1007/s10396-017-0834-1.
    [24]
    QUAIA E, GENNARI AG. The most appropriate time delay after microbubble contrast agent intravenous injection to maximize liver metastasis conspicuity on contrast-enhanced ultrasound[J]. J Med Ultrasound, 2018, 26(3): 128-133. DOI: 10.4103/JMU.JMU_12_17.
    [25]
    CAO DM, JING XX, LIN YW. Enhancement pattern of liver metastasis in contrast-enhanced ultrasonography: An analysis of 76 casess[J]. J Pract Hepatol, 2020, 23(3): 431-434. DOI: 10.3969/j.issn.1672-5069.2020.03.032.

    曹东明, 景香香, 林运旺. 肝转移癌超声造影增强模式表现分析[J]. 实用肝脏病杂志, 2020, 23(3): 431-434. DOI: 10.3969/j.issn.1672-5069.2020.03.032.
    [26]
    DONG Y, ZHANG XL, MAO F, et al. Contrast-enhanced ultrasound features of histologically proven small (≤ 20 mm) liver metastases[J]. Scand J Gastroenterol, 2017, 52(1): 23-28. DOI: 10.1080/00365521.2016.1224380.
    [27]
    LIU X, NE NA, YE XJ, et al. Application of contrast-enhanced ultrasound in differential diagnosis of hepatocellular carcinoma and liver metastases[J]. J Pract Hepatol, 2020, 23(1): 94-97. DOI: 10.3969/j.issn.1672-5069.2020.01.026.

    刘潇, 何年安, 叶显俊, 等. 超声造影对肝细胞癌与肝转移癌的鉴别诊断价值分析[J]. 实用肝脏病杂志, 2020, 23(1): 94-97. DOI: 10.3969/j.issn.1672-5069.2020.01.026.
    [28]
    FENG J, CHANG FL. Application of LI-RADS classification criteria in the identification and diagnosis of hepatocellular carcinoma[J]. Chin Hepatol, 2020, 25(3): 297-299. DOI: 10.3969/j.issn.1008-1704.2020.03.021.

    冯俊, 常凤玲. 超声造影LI-RADS分类标准在肝细胞癌鉴别及诊断中的应用[J]. 肝脏, 2020, 25(3): 297-299. DOI: 10.3969/j.issn.1008-1704.2020.03.021.
    [29]
    ZHANG X, TANG S, HUANG L, et al. Contrast-enhanced sonographic characteristics of hepatic inflammatory pseudotumors[J]. J Ultrasound Med, 2016, 35(9): 2039-2047. DOI: 10.7863/ultra.15.10057.
    [30]
    XIA W, ZHANG WH. Research progress in diagnosis and treatment of pyogenic liver abscess[J]. Med Recapitulate, 2021, 27(13): 2630-2634. DOI: 10.3969/j.issn.1006-2084.2021.13.023.

    夏伟, 张伟辉. 细菌性肝脓肿的诊疗研究进展[J]. 医学综述, 2021, 27(13): 2630-2634. DOI: 10.3969/j.issn.1006-2084.2021.13.023.
    [31]
    FU XB, CHEN JY. Application value of contrast-enhanced ultrasound in the diagnosis of hepatic abscess[J]. Chin Pract Med, 2018, 13(35): 23-24. DOI: 10.14163/j.cnki.11-5547/r.2018.35.010.

    付小兵, 陈纪昀. 超声造影对肝脓肿诊断的应用价值[J]. 中国实用医药, 2018, 13(35): 23-24. DOI: 10.14163/j.cnki.11-5547/r.2018.35.010.
    [32]
    CARAIANI C, BOCA B, BURA V, et al. CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-can things be put together?[J]. Biology (Basel), 2021, 10(5): 412. DOI: 10.3390/biology10050412.
    [33]
    DING J, LONG L, ZHANG X, et al. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS[J]. Eur Radiol, 2021, 31(2): 847-854. DOI: 10.1007/s00330-020-07159-z.
    [34]
    LI L, HU Y, HAN J, et al. Clinical application of liver imaging reporting and data system for characterizing liver neoplasms: a meta-analysis[J]. Diagnostics (Basel), 2021, 11(2): 323. DOI: 10.3390/diagnostics11020323.
    [35]
    DIETRICH CF, AVERKIOU M, NIELSEN MB, et al. How to perform contrast-enhanced ultrasound (CEUS)[J]. Ultrasound Int Open, 2018, 4(1): E2-E15. DOI: 10.1055/s-0043-123931.
    [36]
    SUGIMOTO K, KAKEGAWA T, TAKAHASHI H, et al. Usefulness of modified CEUS LI-RADS for the diagnosis of hepatocellular carcinoma using sonazoid[J]. Diagnostics (Basel), 2020, 10(10): 828. DOI: 10.3390/diagnostics10100828.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (693) PDF downloads(38) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return